What are the implications of FDA approval of PD-1 inhibitors for MSI-high tumors, and what other molecular alterations might trigger immunotherapy based on NGS-generated markers and drivers agnostic to tumor type?

What are the implications of FDA approval of PD-1 inhibitors for MSI-high tumors, and what other molecular alterations might trigger immunotherapy based on NGS-generated markers and drivers agnostic to tumor type?

What are the implications of FDA approval of PD-1 inhibitors for MSI-high tumors, and what other canonical molecular alterations —NTRK and others — do you see on the horizon that might trigger immunotherapy based on NGS-generated markers and drivers agnostic to tumor type?


Created by

CMEducation Resources IQ&A Interactive Intelligence Zone

Presenter

Jean-Charles Soria, MD

Jean-Charles Soria, MD

Professor of Medicine and Medical Oncology South-Paris University Cancer Specialist Institut Gustave Roussy (IGR) Paris, France